Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 6 | 2019 | 105 | 1.710 |
Why?
|
| Arthroplasty, Replacement, Hip | 3 | 2022 | 48 | 1.430 |
Why?
|
| Knee Joint | 2 | 2018 | 129 | 1.200 |
Why?
|
| Pulmonary Embolism | 2 | 2018 | 46 | 1.190 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2018 | 35 | 1.170 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2022 | 93 | 1.090 |
Why?
|
| Neoplasms | 4 | 2022 | 628 | 1.000 |
Why?
|
| Postoperative Complications | 7 | 2022 | 676 | 0.990 |
Why?
|
| Orthopedics | 2 | 2023 | 93 | 0.940 |
Why?
|
| Humans | 39 | 2023 | 29556 | 0.900 |
Why?
|
| Arthroplasty, Replacement, Knee | 3 | 2019 | 85 | 0.860 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 680 | 0.790 |
Why?
|
| Retrospective Studies | 12 | 2022 | 3144 | 0.750 |
Why?
|
| Osteosarcoma | 2 | 2019 | 12 | 0.730 |
Why?
|
| Muscle, Skeletal | 2 | 2016 | 496 | 0.700 |
Why?
|
| Osteoporosis | 1 | 2020 | 52 | 0.700 |
Why?
|
| Shoulder Joint | 1 | 2022 | 124 | 0.690 |
Why?
|
| Sarcoma | 3 | 2018 | 56 | 0.690 |
Why?
|
| Interpersonal Relations | 1 | 2019 | 54 | 0.650 |
Why?
|
| Aged | 15 | 2022 | 9590 | 0.650 |
Why?
|
| Teaching | 1 | 2019 | 55 | 0.640 |
Why?
|
| United States | 10 | 2023 | 3693 | 0.640 |
Why?
|
| Case-Control Studies | 6 | 2022 | 861 | 0.640 |
Why?
|
| Ascorbic Acid | 1 | 2018 | 22 | 0.620 |
Why?
|
| Reimbursement Mechanisms | 1 | 2017 | 11 | 0.610 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 116 | 0.610 |
Why?
|
| Hip Fractures | 1 | 2017 | 30 | 0.600 |
Why?
|
| Musculoskeletal Diseases | 1 | 2018 | 36 | 0.600 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 3764 | 0.590 |
Why?
|
| Nutritional Status | 1 | 2017 | 69 | 0.590 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 163 | 0.590 |
Why?
|
| Antioxidants | 1 | 2018 | 114 | 0.580 |
Why?
|
| Middle Aged | 16 | 2022 | 10936 | 0.580 |
Why?
|
| Patient Readmission | 1 | 2017 | 106 | 0.560 |
Why?
|
| Sarcoma, Experimental | 1 | 2016 | 4 | 0.540 |
Why?
|
| Spasm | 1 | 2016 | 5 | 0.540 |
Why?
|
| Fractures, Bone | 1 | 2017 | 152 | 0.540 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2015 | 29 | 0.500 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2019 | 337 | 0.500 |
Why?
|
| Prostatic Neoplasms | 1 | 2019 | 457 | 0.490 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 64 | 0.480 |
Why?
|
| Angiotensin I | 1 | 2016 | 262 | 0.460 |
Why?
|
| Male | 16 | 2021 | 18012 | 0.460 |
Why?
|
| Vascular Malformations | 1 | 2012 | 8 | 0.430 |
Why?
|
| Peptide Fragments | 1 | 2016 | 423 | 0.430 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2022 | 5 | 0.420 |
Why?
|
| Diphosphonates | 1 | 2012 | 9 | 0.420 |
Why?
|
| Alendronate | 1 | 2012 | 12 | 0.420 |
Why?
|
| Catheter Ablation | 1 | 2012 | 62 | 0.410 |
Why?
|
| Risk Assessment | 1 | 2017 | 1329 | 0.410 |
Why?
|
| Brachytherapy | 1 | 2012 | 22 | 0.410 |
Why?
|
| Fractures, Stress | 1 | 2012 | 11 | 0.410 |
Why?
|
| Femoral Fractures | 1 | 2012 | 39 | 0.400 |
Why?
|
| Carbapenems | 1 | 2021 | 3 | 0.390 |
Why?
|
| Cephalosporins | 1 | 2021 | 7 | 0.390 |
Why?
|
| Mouth Mucosa | 1 | 2021 | 29 | 0.390 |
Why?
|
| Medicare | 4 | 2022 | 189 | 0.380 |
Why?
|
| Circadian Rhythm | 1 | 2020 | 43 | 0.360 |
Why?
|
| Wound Healing | 1 | 2021 | 186 | 0.350 |
Why?
|
| Fasting | 1 | 2020 | 93 | 0.350 |
Why?
|
| Dyslipidemias | 1 | 2020 | 54 | 0.350 |
Why?
|
| Female | 14 | 2021 | 18379 | 0.340 |
Why?
|
| Regenerative Medicine | 1 | 2021 | 192 | 0.320 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2018 | 22 | 0.310 |
Why?
|
| Secondary Prevention | 2 | 2020 | 59 | 0.300 |
Why?
|
| Treatment Outcome | 4 | 2022 | 3128 | 0.300 |
Why?
|
| Cardiology Service, Hospital | 1 | 2017 | 22 | 0.290 |
Why?
|
| Heart Defects, Congenital | 1 | 2017 | 28 | 0.290 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 376 | 0.280 |
Why?
|
| Adult | 8 | 2022 | 8528 | 0.270 |
Why?
|
| Animals | 6 | 2022 | 7339 | 0.270 |
Why?
|
| Dystonia | 1 | 2015 | 12 | 0.250 |
Why?
|
| Risk Factors | 3 | 2020 | 3600 | 0.240 |
Why?
|
| Reoperation | 2 | 2022 | 204 | 0.240 |
Why?
|
| Postural Balance | 1 | 2016 | 163 | 0.230 |
Why?
|
| Length of Stay | 2 | 2017 | 296 | 0.230 |
Why?
|
| Pesticides | 1 | 2016 | 188 | 0.230 |
Why?
|
| Bone Density Conservation Agents | 2 | 2020 | 20 | 0.220 |
Why?
|
| Occupational Exposure | 1 | 2016 | 223 | 0.220 |
Why?
|
| Hypertension | 1 | 2020 | 918 | 0.220 |
Why?
|
| Comorbidity | 3 | 2022 | 548 | 0.220 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 234 | 0.220 |
Why?
|
| Tissue Scaffolds | 2 | 2021 | 392 | 0.220 |
Why?
|
| Transients and Migrants | 1 | 2016 | 280 | 0.220 |
Why?
|
| Obesity | 1 | 2020 | 1081 | 0.220 |
Why?
|
| Employment | 1 | 2023 | 49 | 0.210 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 1058 | 0.210 |
Why?
|
| Prosthesis Failure | 1 | 2022 | 43 | 0.200 |
Why?
|
| Medicaid | 1 | 2022 | 83 | 0.200 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 9 | 0.190 |
Why?
|
| Mice | 3 | 2022 | 2387 | 0.190 |
Why?
|
| Papillomaviridae | 1 | 2020 | 17 | 0.190 |
Why?
|
| Patient Care Team | 2 | 2017 | 124 | 0.190 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 57 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2017 | 875 | 0.180 |
Why?
|
| Decompression, Surgical | 1 | 2021 | 53 | 0.180 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 71 | 0.180 |
Why?
|
| Lumbar Vertebrae | 1 | 2021 | 99 | 0.180 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 984 | 0.180 |
Why?
|
| Hispanic Americans | 1 | 2016 | 903 | 0.170 |
Why?
|
| Osteoblastoma | 1 | 2019 | 1 | 0.170 |
Why?
|
| Transplantation, Heterologous | 1 | 2019 | 121 | 0.170 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2019 | 2 | 0.170 |
Why?
|
| Wounds and Injuries | 1 | 2022 | 251 | 0.170 |
Why?
|
| Comprehension | 1 | 2019 | 19 | 0.170 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2018 | 5 | 0.170 |
Why?
|
| Synovitis, Pigmented Villonodular | 1 | 2018 | 5 | 0.170 |
Why?
|
| Sarcoma, Synovial | 1 | 2018 | 6 | 0.170 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 123 | 0.170 |
Why?
|
| Neurilemmoma | 1 | 2018 | 14 | 0.160 |
Why?
|
| Gout | 1 | 2018 | 14 | 0.160 |
Why?
|
| Multiple Myeloma | 1 | 2018 | 15 | 0.160 |
Why?
|
| Emotions | 1 | 2019 | 48 | 0.160 |
Why?
|
| Lymphoma | 1 | 2018 | 36 | 0.160 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2018 | 15 | 0.160 |
Why?
|
| Osteoarthritis, Knee | 1 | 2019 | 81 | 0.160 |
Why?
|
| Matched-Pair Analysis | 1 | 2017 | 11 | 0.150 |
Why?
|
| Chondrosarcoma | 1 | 2017 | 7 | 0.150 |
Why?
|
| Breast Neoplasms, Male | 1 | 2017 | 11 | 0.150 |
Why?
|
| Complex Regional Pain Syndromes | 1 | 2018 | 19 | 0.150 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2019 | 166 | 0.150 |
Why?
|
| Cryptococcosis | 1 | 2017 | 4 | 0.150 |
Why?
|
| Opportunistic Infections | 1 | 2017 | 9 | 0.150 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 43 | 0.150 |
Why?
|
| Postoperative Period | 1 | 2017 | 92 | 0.150 |
Why?
|
| Osteomyelitis | 1 | 2017 | 22 | 0.150 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 89 | 0.150 |
Why?
|
| ROC Curve | 1 | 2017 | 149 | 0.150 |
Why?
|
| Hand | 1 | 2017 | 63 | 0.150 |
Why?
|
| Osteoarthritis | 1 | 2017 | 74 | 0.140 |
Why?
|
| Odds Ratio | 1 | 2017 | 448 | 0.140 |
Why?
|
| Dietary Supplements | 1 | 2018 | 172 | 0.140 |
Why?
|
| Bone Density | 1 | 2018 | 183 | 0.140 |
Why?
|
| Acrospiroma | 1 | 2016 | 2 | 0.140 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2016 | 5 | 0.140 |
Why?
|
| Arthroscopy | 1 | 2018 | 205 | 0.140 |
Why?
|
| Muscle Neoplasms | 1 | 2016 | 8 | 0.140 |
Why?
|
| Mice, Inbred Strains | 1 | 2016 | 43 | 0.140 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 638 | 0.130 |
Why?
|
| Hindlimb | 1 | 2016 | 57 | 0.130 |
Why?
|
| Biopsy, Needle | 1 | 2016 | 90 | 0.130 |
Why?
|
| Fibrosis | 1 | 2016 | 104 | 0.130 |
Why?
|
| Logistic Models | 1 | 2017 | 729 | 0.130 |
Why?
|
| Reference Values | 1 | 2016 | 225 | 0.130 |
Why?
|
| Random Allocation | 1 | 2016 | 214 | 0.130 |
Why?
|
| Cell Differentiation | 2 | 2022 | 438 | 0.130 |
Why?
|
| Carcinoma | 1 | 2016 | 89 | 0.130 |
Why?
|
| Bone Nails | 1 | 2015 | 29 | 0.130 |
Why?
|
| Fracture Fixation, Intramedullary | 1 | 2015 | 34 | 0.120 |
Why?
|
| Analysis of Variance | 1 | 2016 | 455 | 0.120 |
Why?
|
| Bone Plates | 1 | 2015 | 68 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 533 | 0.120 |
Why?
|
| Radius Fractures | 1 | 2015 | 58 | 0.120 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 520 | 0.120 |
Why?
|
| Disease Progression | 1 | 2016 | 574 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2015 | 113 | 0.120 |
Why?
|
| Joint Instability | 1 | 2015 | 72 | 0.120 |
Why?
|
| Young Adult | 3 | 2019 | 2431 | 0.110 |
Why?
|
| Phlebography | 1 | 2012 | 26 | 0.110 |
Why?
|
| Veins | 1 | 2012 | 29 | 0.110 |
Why?
|
| Lymphocyte Activation | 1 | 2022 | 82 | 0.110 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2022 | 8 | 0.110 |
Why?
|
| Lymph Nodes | 1 | 2022 | 94 | 0.100 |
Why?
|
| Wound Infection | 1 | 2012 | 11 | 0.100 |
Why?
|
| Adolescent | 3 | 2019 | 3284 | 0.100 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2012 | 32 | 0.100 |
Why?
|
| Imidazoles | 1 | 2012 | 104 | 0.100 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 101 | 0.100 |
Why?
|
| Epithelium | 1 | 2021 | 21 | 0.100 |
Why?
|
| Gram-Negative Bacteria | 1 | 2021 | 7 | 0.100 |
Why?
|
| Radiography | 1 | 2012 | 355 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 525 | 0.090 |
Why?
|
| Ketone Bodies | 1 | 2020 | 6 | 0.090 |
Why?
|
| Mutation | 1 | 2022 | 475 | 0.090 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 119 | 0.090 |
Why?
|
| Databases, Factual | 2 | 2021 | 333 | 0.080 |
Why?
|
| Oxidative Stress | 1 | 2020 | 224 | 0.080 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2018 | 19 | 0.080 |
Why?
|
| Virus Diseases | 1 | 2018 | 19 | 0.080 |
Why?
|
| Hospitalization | 2 | 2022 | 423 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2018 | 71 | 0.070 |
Why?
|
| Thoracic Surgery | 1 | 2017 | 5 | 0.070 |
Why?
|
| Child | 2 | 2019 | 2234 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2022 | 1701 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 1225 | 0.070 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2017 | 50 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2018 | 372 | 0.070 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2017 | 71 | 0.070 |
Why?
|
| Program Evaluation | 1 | 2017 | 176 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2018 | 576 | 0.060 |
Why?
|
| Age Factors | 1 | 2017 | 1120 | 0.060 |
Why?
|
| North Carolina | 1 | 2016 | 1430 | 0.050 |
Why?
|
| Trauma Centers | 1 | 2022 | 88 | 0.050 |
Why?
|
| Lumbosacral Region | 1 | 2021 | 12 | 0.050 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2020 | 1 | 0.050 |
Why?
|
| Germinal Center | 1 | 2020 | 5 | 0.050 |
Why?
|
| Diskectomy | 1 | 2021 | 13 | 0.050 |
Why?
|
| Laminectomy | 1 | 2021 | 16 | 0.050 |
Why?
|
| Plasma Cells | 1 | 2020 | 8 | 0.050 |
Why?
|
| Immunity, Humoral | 1 | 2020 | 12 | 0.050 |
Why?
|
| Spinal Fusion | 1 | 2021 | 42 | 0.050 |
Why?
|
| Cell Separation | 1 | 2020 | 87 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 105 | 0.050 |
Why?
|
| Bone Substitutes | 1 | 2019 | 8 | 0.040 |
Why?
|
| Papillomavirus Infections | 1 | 2020 | 54 | 0.040 |
Why?
|
| Osteoblasts | 1 | 2019 | 46 | 0.040 |
Why?
|
| Cell Dedifferentiation | 1 | 2019 | 2 | 0.040 |
Why?
|
| Sclerosis | 1 | 2019 | 10 | 0.040 |
Why?
|
| Osteogenesis | 1 | 2019 | 77 | 0.040 |
Why?
|
| Swine | 1 | 2019 | 204 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 149 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 96 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 1 | 2019 | 106 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 198 | 0.040 |
Why?
|
| Curettage | 1 | 2018 | 9 | 0.040 |
Why?
|
| Bone Cements | 1 | 2018 | 10 | 0.040 |
Why?
|
| Bone Transplantation | 1 | 2018 | 47 | 0.040 |
Why?
|
| Tibia | 1 | 2018 | 56 | 0.040 |
Why?
|
| Cell Line | 1 | 2019 | 456 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 75 | 0.040 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2017 | 2 | 0.040 |
Why?
|
| Hepatitis C, Chronic | 1 | 2018 | 77 | 0.040 |
Why?
|
| Itraconazole | 1 | 2017 | 6 | 0.040 |
Why?
|
| Obesity, Morbid | 1 | 2018 | 55 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2017 | 34 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 396 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 43 | 0.040 |
Why?
|
| Patient Selection | 1 | 2019 | 257 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 713 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 727 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 796 | 0.040 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 121 | 0.040 |
Why?
|
| Fractures, Closed | 1 | 2015 | 9 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2015 | 47 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 272 | 0.030 |
Why?
|
| Wrist Joint | 1 | 2015 | 53 | 0.030 |
Why?
|
| Range of Motion, Articular | 1 | 2015 | 178 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 494 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 314 | 0.030 |
Why?
|
| Tissue Engineering | 1 | 2019 | 617 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2015 | 215 | 0.030 |
Why?
|
| Pain, Postoperative | 1 | 2015 | 175 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2015 | 248 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2015 | 2046 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 2124 | 0.020 |
Why?
|